Research Programme: nucleotide-competing reverse transcriptase inhibitors - Tibotec
Alternative Names: NCRTI-1Latest Information Update: 04 Nov 2017
At a glance
- Originator McGill University; Tibotec BVBA
- Class Pyridones; Small molecules
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Belgium
- 20 Feb 2008 This programme is still in active development
- 22 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral infections antimicrobial activity section